Jornayvaz François R, Gariani Karim
Service d'endocrinologie, diabétologie, nutrition et éducation du patient, HUG, 1211 Genève 14.
Rev Med Suisse. 2020 Jan 15;16(676-7):31-33.
Diabetes is a rapidly evolving discipline, numerous new molecules and recommendations are available. This allows for a better follow up of our patients. Moreover, every new molecule devoted to treat type 2 diabetes must undergo a cardiovascular safety study. In recent years, some of these studies revealed beneficial cardiovascular and/or renal effects, which represents a benefit for our patients. Nevertheless, this pharmacological plethora is paradoxically associated with clinical inertia as general practitioners may be in trouble finding the right medication. This article will highlight novelties in the field of diabetes during the year 2019.
糖尿病是一个快速发展的学科，有众多新的分子和建议可供参考。这使得我们能够更好地跟踪我们的患者。此外，每一种用于治疗2型糖尿病的新分子都必须进行心血管安全性研究。近年来，其中一些研究揭示了有益的心血管和/或肾脏效应，这对我们的患者来说是一项益处。然而，矛盾的是，这种药理学上的过多药物与临床惰性相关，因为全科医生可能难以找到合适的药物。本文将重点介绍2019年糖尿病领域的新进展。
